BioSpace News Archive

Erimos Pharmaceuticals, LLC announced today, in collaboration with Adult Brain Tumor Consortium (ABTC) and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, initiation of a multi-center phase I clinical study of their lead compound, terameprocol (EM-1421) in patients with High Grade Glioma (Grade III or IV).

Cohen Children’s Medical Center has earned top 50 national rankings for exceptional care in eight pediatric specialties, according to US News & World Report’s 2018-19 Best Children’s Hospitals.

Boston Children’s Hospital recognized as nation’s No. 1 pediatric hospital for the fifth consecutive year

Carolyn Chamberlain joins Assure BrandPanels with 20+ years of experience in pharmaceutical market research

Achieve Life Sciences, Inc. announced positive results from a series of drug metabolism, drug-drug interaction and transporter studies with cytisine, the Company’s product candidate being evaluated as an aid to smoking cessation.

Skyhawk and Celgene enter into a five-year strategic collaboration. Celgene to receive exclusive options to license a number of Skyhawk’s product candidates focused on high-value targets in neurological indications in return for an upfront fee, and potential future license fees, milestone payments, and royalties

Rigel selected R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) preclinical development program, for human clinical trials.

Alongside its recently announced strategic collaboration, the Company has closed a new $40 million all-common stock equity investment by its strategic collaborators, major family investors, and leading venture funds

BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need, announced today the appointment of Scott D. Myers as chairman of Board of Directors.

Positive trend vote recommending the approval of the Marketing Authorisation Application (MAA) for neratinib for the extended adjuvant treatment of early stage HER2-positive hormone receptor positive breast cancer.